SCHEMBL23478353

SCHEMBL23478353

CC(C)(C)c1[nH]c2ccncc2c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 4/20 0.47
▸ KIF11 P52732 1/20 0.43
▸ MAPK14 Q16539 1/20 0.41
▸ PARP1 P09874 1/20 0.40
▸ MAPT P10636 8/20 0.39
▸ CHUK O15111 3/20 0.39
▸ FEN1 P39748 1/20 0.38
▸ HTR6 P50406 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ GABRP O00591 1/20 0.37
▸ GABRD O14764 1/20 0.37
▸ IKBKB O14920 1/20 0.37
▸ AURKA O14965 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ PIM1 P11309 1/20 0.37
▸ TOP1 P11387 1/20 0.37
▸ GABRA1 P14867 1/20 0.37
▸ IDO1 P14902 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ GABRB1 P18505 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22792801 0.81 ACHE (0.46) ACHEKIF11MAPK14PARP1MAPT
SCHEMBL23473995 0.77 ACHE (0.51) ACHEKIF11MAPK14PARP1MAPT
SCHEMBL27447021 0.72 ACHE (0.47) ACHEKIF11MAPK14PARP1MAPT
SCHEMBL23511225 0.72 ACHE (0.47) ACHEKIF11MAPK14PARP1MAPT
SCHEMBL22792912 0.70 ACHE (0.49) ACHEKIF11MAPK14PARP1MAPT
SCHEMBL21672433 0.70 L3MBTL1 (0.47) KIF11PARP1MAPTCHUKKDM4E
SCHEMBL22792807 0.70 CHUK (0.46) KIF11PARP1CHUKKDM4EGABRP
SCHEMBL972999 0.70 ACHE (0.78) ACHEKIF11PARP1MAPTCHUK
SCHEMBL29642993 0.70 ACHE (0.78) ACHEKIF11PARP1MAPTCHUK
SCHEMBL23478373 0.69 HTR6 (0.51) ACHEKIF11MAPK14PARP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 — — US disclosed
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 — — US disclosed
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 — — US disclosed
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 — — US disclosed
US-20210171461-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 — — US disclosed
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ACHE 2723/4885KIF11 3394/4885MAPK14 2625/4885
US-11807641-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 ACHE 2723/4885KIF11 3394/4885MAPK14 2625/4885
US-12030853-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 ACHE 2723/4885KIF11 3394/4885MAPK14 2625/4885
US-20210171461-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ACHE 2723/4885KIF11 3394/4885MAPK14 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback